Switching from Sitagliptin to Liraglutide Can Control Hyperglyciemia in Some With Type 2 Diabetes

MedicalResearch.com Interview with:

Dr. Maximo Maislos MD Head of the Atherosclerosis and Metabolism Unit Department of Medicine of the Soroka University Medical Center Israel

Dr. Maximo Maislos

Dr. Maximo Maislos MD
Head of the Atherosclerosis and Metabolism Unit
Department of Medicine of the Soroka University Medical Center
Israel

MedicalResearch.com: What is the background for this study? What are the main findings?

Dr. Maislos: When diet and exercise are insufficient, Type 2 Diabetes Mellitus patients are generally started on metformin, and when intensification is required, a drug is recommended.

The incretin family of drugs includes oral DPP-4 inhibitors and injectable glucagon-like peptide-1 receptor agonist (GLP-1RA). Both are equally recommended as a second-line therapy by the American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) position statement.

We hypothesized that by switching insufficiently controlled subjects on metformin+sitagliptin (DPP-41) to metformin+liraglutide (GLP-1 RA), more patients with type 2 diabetes would achieve better glycemic control without needing to add a third antidiabetic agent.

In our study we were able to show that subjects insufficiently controlled on sitagliptin who switch to liraglutide can obtain clinically relevant reductions in glycemia and body weight, without compromising safety. A switch from sitagliptin to liraglutide provides an option for improved management of type 2 diabetes while still allowing patients to remain on dual therapy.

MedicalResearch.com: What should clinicians and patients take away from your report? 

Dr. Maislos: It is possible to achieve better glycemic control by switching  from sitagliptin (DPP-4i) to liraglutide and maintaining the patient in a two drug therapeutic regime.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Dr. Maislos:  Treatment of diabetes mellitus should be individualized, tailored to the patient’s  specific needs.

MedicalResearch.com: Is there anything else you would like to add? 

Dr. Maislos:  Treatment of diabetes mellitus should be individualized, tailored to the patient’s  specific needs.

Citation: Abstract presented at the 2016 ENDO Meeting, April 2016

Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes: a randomized, double-blind, double-dummy, active-controlled 26-week trial

Timothy S Bailey1, Róbert Takács2, Francisco Tinahones Madueño3, Anne Bloch Thomsen4, Margit Staum Kaltoft4 and Maximo Maislos*5
1AMCR Institute Inc., Escondido, CA, 2University of Szeged, Szeged, Hungary, 3University of Málaga, CIBERobn, Instituto de Salud Carlos III, Málaga, Spain, 4Novo Nordisk A/S, Søborg, Denmark, 5Soroka University Medical Center, Beer Sheva, Israel

Dr. Maximo Maislos MD (2016). Switching from Sitagliptin to Liraglutide Can Control Hyperglyciemia in Some With Type 2 Diabetes MedicalResearch.com

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.